• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

cafead

Administrator
Staff member
  • cafead   May 06, 2024 at 06:12: PM
via Vertex Pharmaceuticals (VRTX.O) beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments.

Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation.

article source